Publication: Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease
Issued Date
2013-01-01
Resource Type
ISSN
15280012
00165085
00165085
Other identifier(s)
2-s2.0-84884416525
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Gastroenterology. Vol.145, No.4 (2013)
Suggested Citation
Paul Angulo, Elisabetta Bugianesi, Einar S. Bjornsson, Phunchai Charatcharoenwitthaya, Peter R. Mills, Francisco Barrera, Svanhildur Haflidadottir, Christopher P. Day, Jacob George Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology. Vol.145, No.4 (2013). doi:10.1053/j.gastro.2013.06.057 Retrieved from: https://repository.li.mahidol.ac.th/handle/20.500.14594/32700
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Simple noninvasive systems predict long-term outcomes of patients with nonalcoholic fatty liver disease
Abstract
Background & Aims Some patients with nonalcoholic fatty liver disease (NAFLD) develop liver-related complications and have higher mortality than other patients with NAFLD. We determined the accuracy of simple, noninvasive scoring systems in identification of patients at increased risk for liver-related complications or death. Methods We performed a retrospective, international, multicenter cohort study of 320 patients diagnosed with NAFLD, based on liver biopsy analysis through 2002 and followed through 2011. Patients were assigned to mild-, intermediate-, or high-risk groups based on cutoff values for 2 of the following: NAFLD fibrosis score, aspartate aminotransferase/platelet ratio index, FIB-4 score, and BARD score. Outcomes included liver-related complications and death or liver transplantation. We used multivariate Cox proportional hazard regression analysis to adjust for relevant variables and calculate adjusted hazard ratios (aHRs). Results During a median follow-up period of 104.8 months (range, 3-317 months), 14% of patients developed liver-related events and 13% died or underwent liver transplantation. The aHRs for liver-related events in the intermediate-risk and high-risk groups, compared with the low-risk group, were 7.7 (95% confidence interval [CI]: 1.4-42.7) and 34.2 (95% CI: 6.5-180.1), respectively, based on NAFLD fibrosis score; 8.8 (95% CI: 1.1-67.3) and 20.9 (95% CI: 2.6-165.3) based on the aspartate aminotransferase/platelet ratio index; and 6.2 (95% CI: 1.4-27.2) and 6.6 (95% CI: 1.4-31.1) based on the BARD score. The aHRs for death or liver transplantation in the intermediate-risk and high-risk groups compared with the low-risk group were 4.2 (95% CI: 1.3-13.8) and 9.8 (95% CI: 2.7-35.3), respectively, based on the NAFLD fibrosis scores. Based on aspartate aminotransferase/platelet ratio index and FIB-4 score, only the high-risk group had a greater risk of death or liver transplantation (aHR = 3.1; 95% CI: 1.1-8.4 and aHR = 6.6; 95% CI: 2.3-20.4, respectively). Conclusions Simple noninvasive scoring systems help identify patients with NAFLD who are at increased risk for liver-related complications or death. NAFLD fibrosis score appears to be the best indicator of patients at risk, based on HRs. The results of this study require external validation. © 2013 by the AGA Institute.